NCI Cancer Bulletin: A Trusted Source for Cancer Research NewsNCI Cancer Bulletin: A Trusted Source for Cancer Research News
June 27, 2006 • Volume 3 / Number 26 E-Mail This Document  |  Download PDF  |  Bulletin Archive/Search  |  Subscribe

NCI Cancer Bulletin Archive

Page Options

  • Print This Page
  • Print This Document
  • View Entire Document
  • Email This Document
  • View/Print PDF

The information and links on this page are no longer being updated and are provided for reference purposes only.

FDA Update

FDA Approves First Drug Treatment for Late-Stage Cervical Cancer

Topotecan hydrochloride (Hycamtin) was approved by the Food and Drug Administration (FDA) for use in combination with cisplatin for Stage IVB, recurrent, or persistent cancer of the cervix. This chemotherapy treatment improved survival in clinical trials by about 50 percent over cisplatin alone, from 6.5 to 9.4 months, and "is a potentially life-prolonging option for thousands of women," said Acting FDA Commissioner Dr. Andrew von Eschenbach.

The drug's side effects are serious, however, including a drop in white blood cells and platelets. The approval also stipulates that a patient's physician must determine that surgery or radiation therapy is not likely to be effective. Produced by GlaxoSmithKline, the drug is already approved for ovarian and small-cell lung cancers.